Does Dr. KENNETH BRAMLETT have financial conflicts of interest?

Dr. KENNETH BRAMLETT (M.D.) has received a total of $1,736 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $1,736 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. KENNETH BRAMLETT?

According to CMS Open Payments data, Dr. KENNETH BRAMLETT received funding from ZIMMER BIOMET HOLDINGS ($536), HIKMA PHARMACEUTICALS USA ($423), and ETHICON US ($215).

Does Dr. KENNETH BRAMLETT receive research grants or speaking fees?

Dr. KENNETH BRAMLETT has received $1,736 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. KENNETH BRAMLETT

M.D.Real-Time Hydrated

Specialty: Orthopaedic Surgery, Sports Medicine

Practice Location: VESTAVIA HILLS, AL 35216

NPI Number: 1164449518

LIFETIME INDUSTRY VALUE

$1,736

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. BRAMLETT is a verified Orthopaedic Surgery, Sports Medicine practitioner based in VESTAVIA HILLS, AL.

Between 2021 and 2024, Dr. BRAMLETT had an overall industry promotional and research financial footprint of $1,736 as recorded in the federal CMS Open Payments database.

$1,736 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. BRAMLETT's primary funding source is ZIMMER BIOMET HOLDINGS, which accounts for $536 (representing 30.9% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ZIMMER BIOMET HOLDINGS

Rank 1

$536

30.9%

HIKMA PHARMACEUTICALS USA

Rank 2

$423

24.4%

ETHICON US

Rank 3

$215

12.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.